A Splendid New Beginning at the End of a 40-Year Quest: The First KRASG12D Inhibitor in Pancreatic Cancer.
A Splendid New Beginning at the End of a 40-Year Quest: The First KRASG12D Inhibitor in Pancreatic Cancer.
复制标题
40 年探索结束后的辉煌新起点：第一个治疗胰腺癌的 KRASG12D 抑制剂。
DOI：
10.1158/2159-8290.cd-22-1304
复制
发表时间：
2023
期刊：
影响因子：
28.2
通讯作者：
Grabocka,Elda
中科院分区：
文献类型：
--
作者：
Redding,Alexandra;Grabocka,Elda
第一种KRASG12D抑制剂MRTX113作为单药治疗在PDAC的多种小鼠模型中导致消退。MRTX 113阻断癌细胞增殖，诱导癌细胞死亡，促进免疫浸润和激活。参见肯普等人的相关文章，第298（6）页。
SummaryThe first KRASG12Dinhibitor, MRTX113, leads to regression in multiple mouse models of PDAC as a monotherapy. MRTX113 blocks cancer cell proliferation, induces cancer cell death, and promotes immune infiltration and activation.See related article by Kemp et al., p. 298 (6).